Apple, Chevron, Biogen fall premarket; Univar, Pinduoduo rise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Pinduoduo Inc. (PDD) PT Raised to $107 at Goldman Sachs
November 28, 2022 5:21 PM ESTGoldman Sachs analyst Ronald Keung raised the price target on Pinduoduo Inc. (NASDAQ: PDD) to $107.00 (from $95.00) while maintaining a Buy rating following earnings.
The analyst commented, "Factoring in strong 3Q results, we lift our revenue estimates by +8% to +12% and adj. operating profit... More
Apple (AAPL) threatened to withhold Twitter from App Store says Musk
November 28, 2022 4:26 PM ESTElon Musk said in a series of tweets on Monday that Apple (NASDAQ: AAPL) threatened to withhold Twitter from its App Store without providing a reason why.
The Twitter owner and Tesla CEO tweeted: "Apple has also threatened to withhold Twitter from its App Store, but won't tell us... More
Sony to supply state-of-the-art image sensors for the next Apple (AAPL) iPhone - Nikkei
November 28, 2022 3:21 PM EST(Updated - November 28, 2022 3:22 PM EST)
The next Apple (NASDAQ: AAPL) iPhone series will be equipped with Sony Group's latest state-of-the-art image sensor, according to a report by Nikkei on Monday.
The sensor will be supplied to Apple... More
Recession impacts on Williams-Sonoma (WSM) 'appear underestimated'
November 28, 2022 2:06 PM ESTRetailer Williams-Sonoma (NYSE: WSM) was cut to Underweight from Equal-Weight by Morgan Stanley analyst Simeon Gutman on Monday, also lowering the firm's price target on the stock to $100 per share from $150.
Gutman told investors in a research note that earnings revisions could turn sharply negative in 2023 as the "impacts of reversion, recession & normalizing promotions appear... More
Pinduoduo Inc. (PDD) PT Raised to $85 at US Tiger Securities
November 28, 2022 11:39 AM ESTUS Tiger Securities analyst Bo Pei raised the price target on Pinduoduo Inc. (NASDAQ: PDD) to $85.00 (from $80.00) while maintaining a Buy rating following earnings.
The analyst commented, "We are maintaining our BUY rating and raising our price target to $85 (was $80) after PDD beat 3Q revenue and profit estimates by a wide margin with... More
Univar (UNVR) Could Be Seeking a Takeover at $40/Share Plus - Deutsche Bank
November 28, 2022 11:22 AM ESTDeutsche Bank analyst David Begleiter weighed in on Univar Solutions Inc. (NYSE: UNVR) after the company confirmed that it has received a preliminary indication of interest from Brenntag SE regarding a potential takeover.
Begleiter believes Univar could be seeking an acquisition price of... More
Biogen (BIIB) Stock Falls on Alzheimer's Drug Trial Death Reports
November 28, 2022 10:05 AM ESTBiogen (NASDAQ: BIIB) shares dipped Monday after a report by Science.org stated that a woman participating in a trial of experimental Alzheimer's treatment lecanemab had recently died from a brain hemorrhage.
According to the report, some researchers linked the brain hemorrhage to the drug. It is said to be the second death thought to be associated with lecanemab,... More
Truist Securities Weighs in on Biogen (BIIB) Following 2nd Reported Alzheimer's Death
November 28, 2022 9:26 AM ESTTruist Securities analyst Robyn Karnauskas weighed in on Biogen (NASDAQ: BIIB) following recent news of the second death reported for Alzheimer's drug lecanemab. The analyst highlights:
The recent news and AEs of the drug raise lots of questions whether... More
